AVN944

PreclinicalSmall molecule

Vertex Pharmaceuticals

AVN944 is one of 17 small molecule programs targeting Advanced Stage. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced StageWithdrawn

Advanced StagePreclinical

Withdrawn

Competition

Competitive Landscape

17 competitors in Advanced Stage

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

2 2

DTIC-Dome

Bayer

Phase 3

1 3

Adcetris

Pfizer

Phase 3

1 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

3 5

Vepesid

AAvyxa

Phase 3

2 6

Decadron

AAspen Global Incorporated

Phase 3

1 7

Nexavar

Bayer

Phase 2

2 8

Cabometyx

Bristol-Myers Squibb

Phase 2

1 9

Stivarga

Bayer

Phase 2

1 10

Imfinzi

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced Stage1 trial

A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors

Withdrawn· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·N/A·NCT00923728

Pancreatic Cancer1 trial

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

Terminated· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 2·NCT00493441·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AVN944. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AVN944 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AVN944. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vertex Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Vertex Pharmaceuticals

AVN944

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced Stage1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News